217 related articles for article (PubMed ID: 23860204)
1. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Moebus V; Jackisch C; Schneeweiss A; Huober J; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Runnebaum IB; Hinke A; Kreienberg R; Untch M;
J Natl Cancer Inst; 2013 Jul; 105(14):1018-26. PubMed ID: 23860204
[TBL] [Abstract][Full Text] [Related]
2. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M
J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
[TBL] [Abstract][Full Text] [Related]
4. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of epoetin alfa in critically ill patients.
Corwin HL; Gettinger A; Fabian TC; May A; Pearl RG; Heard S; An R; Bowers PJ; Burton P; Klausner MA; Corwin MJ;
N Engl J Med; 2007 Sep; 357(10):965-76. PubMed ID: 17804841
[TBL] [Abstract][Full Text] [Related]
6. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
[TBL] [Abstract][Full Text] [Related]
7. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M; Fasching PA; Konecny GE; von Koch F; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Schuster T; Nekljudova V; Lebeau A; Loibl S; von Minckwitz G;
Ann Oncol; 2011 Sep; 22(9):1988-1998. PubMed ID: 21385882
[TBL] [Abstract][Full Text] [Related]
8. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
9. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
10. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Untch M; von Minckwitz G; Konecny GE; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Beckmann MW; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Nekljudova V; Lebeau A; Loibl S; Fasching PA;
Ann Oncol; 2011 Sep; 22(9):1999-2006. PubMed ID: 21382868
[TBL] [Abstract][Full Text] [Related]
11. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
O'Shaughnessy JA; Vukelja SJ; Holmes FA; Savin M; Jones M; Royall D; George M; Von Hoff D
Clin Breast Cancer; 2005 Feb; 5(6):439-46. PubMed ID: 15748464
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Pronzato P; Cortesi E; van der Rijt CC; Bols A; Moreno-Nogueira JA; de Oliveira CF; Barrett-Lee P; Ostler PJ; Rosso R;
Oncologist; 2010; 15(9):935-43. PubMed ID: 20798194
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
Demetri GD; Kris M; Wade J; Degos L; Cella D
J Clin Oncol; 1998 Oct; 16(10):3412-25. PubMed ID: 9779721
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
18. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
19. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
[TBL] [Abstract][Full Text] [Related]
20. RE: Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Gross I; Auerbach M
J Natl Cancer Inst; 2014 Mar; 106(3):djt451. PubMed ID: 24586092
[No Abstract] [Full Text] [Related]
[Next] [New Search]
